AlphAIalphai — Financial news for AI agents
rttnews.comSEP 12 min read$ALMS

Alumis Phase 2b LUMUS Trial Misses Endpoints; Stock Plunges

Alumis Inc. (ALMS) reported Phase 2b LUMUS trial results for Envudeucitinib in SLE, missing primary and secondary endpoints overall but showing promise in a subset of patients with high interferon gene signature. The drug demonstrated improvements in several measures in this subgroup and was well tolerated. The company plans to discuss Phase 3 development with regulators. ALMS stock fell over 55% in pre-market trading.

Original reporting
rttnews.com
Published Sep 1, 2026, 6:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 1, 2026, 6:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefTechnology
Primary signal
$ALMS
Bearish
high confidence
Mentioned
$ALMS
Relevance
8/10
alphai data visualization · based on rttnews.com
Decision brief

The 30-second read

$ALMSBearishMed
01

Why it matters

The missed endpoints raise questions about the drug's efficacy in the broader SLE population, potentially delaying regulatory milestones.

02

Market read

Significant negative catalyst for ALMS; may influence related biotech stocks.

03

What to watch

Upcoming NDA for psoriasis could offset trial disappointment if data remain positive.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Alumis Inc. (ALMS) focuses on interferon‑pathway inhibitors for autoimmune diseases.

Company-level read

Ticker impact

$ALMSBearishHigh confidence
Context

Alumis reported Phase 2b LUMUS trial missed primary and secondary endpoints, causing stock to drop 55% in pre‑market.

Expected impact

Downward pressure; potential further sell‑off.

Evidence & confidence

First disclosure of missed endpoints, significant price move, and uncertainty around Phase 3 plans.

Market effects

Sector

May dampen sentiment in the autoimmune‑biotech sector.

Regional

Limited to US biotech investors.

Global

Low; primarily affects niche SLE therapeutic space.

Counterpoint

What could challenge this read

IFNGS‑high subgroup showed strong response; could spark a rebound if Phase 3 succeeds.

Key entities

  • company
    Alumis Inc.

    Biotech developing Envudeucitinib.

  • executive
    Dr. Jörn Drappa

    Chief Medical Officer of Alumis.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 1
$ALMSHighAI 8/10

Why is Alumis stock collapsing today?

Alumis stock fell 54.2% in pre-market trading after its Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus missed primary and secondary endpoints. A subgroup of patients showed positive responses, but the overall trial population was under-represented. The company plans to discuss a Phase 3 program with regulators. The Nasdaq, S&P 500, and Dow Jones also declined, exacerbating the sell-off.

investing.com2 min
SEP 1
$ALMSHighAI 8/10

Alumis stock tumbles 55% after lupus drug trial misses goals

Alumis Inc. (ALMS) shares dropped 55% after its Phase 2b LUMUS trial for envudeucitinib in lupus failed primary and secondary endpoints. The trial enrolled 408 patients but showed improvements only in a subgroup with high interferon gene signature (IFNGS-high). The drug was well-tolerated, and the company plans to discuss Phase 3 development for this subgroup with regulators. Alumis remains on track to submit a New Drug Application for psoriasis in Q4 2026.

investing.com2 min
SEP 1
$ALMSLowAI 8/10

Alumis Inc.: Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)

Alumis Inc. (ALMS) reported that its Phase 2b LUMUS trial of envudeucitinib for systemic lupus erythematosus (SLE) did not meet primary and secondary endpoints in the overall population. However, a prespecified subgroup of patients with high interferon gene signature (IFNGS-high) showed robust responses. The company plans to discuss Phase 3 development with regulators. Envudeucitinib was well tolerated. Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psor

finanznachrichten.de2 min
AUG 13
$ALMSMed

ALUMIS INC. (ALMS): Results of Operations and Financial Condition

ALUMIS INC. (ALMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Exhibit 99.1 ​ ​ Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements ​ – ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO – ​ – Alumis remains on track to

SEC EDGAR 8-K6 min